In March, IntelGenx Technologies Corp. (IGX) announced that its wholly-owned subsidiary, IntelGenx Corp, has agreed to a strategic partnership with atai Life Sciences (ATAI), one of the industry’s largest clinical-stage biopharmaceutical companies aiming to transform the treatment of mental health disorders. In connection with this partnership, atai acquired ~25% of IntelGenx for approximately $12.3 million…

You must have PRO to access this content.